Goel Ruchika, Josephson Cassandra D
Division of Transfusion Medicine, Department of Pathology and Division of Pediatric Hematology/Oncology, Department of Pediatrics, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY, USA.
Departments of Pathology and Pediatrics, Center for Transfusion and Cellular Therapies, Emory University School of Medicine and AFLAC Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Atlanta, GA, USA.
F1000Res. 2018 May 18;7. doi: 10.12688/f1000research.13979.1. eCollection 2018.
Transfusions of red blood cells (RBCs), platelets, and plasma are critical therapies for infants and neonates (particularly preterm neonates) in the neonatal intensive care unit, who are the most frequently transfused subpopulation across all ages. Although traditionally a significant gap has existed between the blood utilization and the evidence base essential to adequately guide transfusion practices in infants and neonates, pediatric transfusion medicine is evolving from infancy and gradually coming of age. It is entering an exciting era with recognition as an independent discipline, a new and evolving high-quality evidence base for transfusion practices, novel technologies and therapeutics, and national/international collaborative research, educational, and clinical efforts. Triggers and thresholds for red cell transfusion are accumulating evidence with current phase III clinical trials. Ongoing trials and studies of platelet and plasma transfusions in neonates are anticipated to provide high-quality evidence in years to come. This article aims to summarize the most current evidence-based practices regarding blood component therapy in neonates. Data on the use of specific components (RBCs, plasma, and platelets) are provided. We attempt to define thresholds for anemia, thrombocytopenia, and abnormal coagulation profile in neonates to highlight the difficulties in having a specific cutoff value in neonates and preterm infants. Indications for transfusion of specific products, transfusion thresholds, and current practices and guidelines are provided, and possible adverse outcomes and complications are discussed. Finally, the critical research knowledge gaps in these practices as well as ongoing and future research areas are discussed. In an era of personalized medicine, neonatal transfusion decisions guided by a strong evidence base must be the overarching goal, and this underlies all of the strategic initiatives in pediatric and neonatal transfusion research highlighted in this article.
红细胞(RBC)、血小板和血浆输注是新生儿重症监护病房中婴儿和新生儿(尤其是早产儿)的关键治疗方法,他们是所有年龄段中输血最频繁的亚群体。尽管传统上血液利用与充分指导婴儿和新生儿输血实践所需的证据基础之间存在显著差距,但儿科输血医学正从起步阶段不断发展并逐渐走向成熟。它正在进入一个令人兴奋的时代,被认可为一门独立学科,拥有用于输血实践的全新且不断发展的高质量证据基础、新技术和治疗方法,以及国家/国际合作研究、教育和临床努力。红细胞输血的触发因素和阈值在当前的III期临床试验中积累了证据。预计未来几年正在进行的新生儿血小板和血浆输注试验和研究将提供高质量证据。本文旨在总结目前关于新生儿血液成分治疗的循证实践。提供了关于特定成分(红细胞、血浆和血小板)使用的数据。我们试图确定新生儿贫血、血小板减少症和异常凝血状况的阈值,以突出在新生儿和早产儿中确定特定临界值的困难。提供了特定产品输血的适应症、输血阈值以及当前的实践和指南,并讨论了可能的不良后果和并发症。最后,讨论了这些实践中关键的研究知识空白以及正在进行和未来的研究领域。在个性化医疗的时代,以强有力的证据基础为指导做出新生儿输血决策必须是首要目标,这也是本文所强调的儿科和新生儿输血研究中所有战略举措的基础。